Lonza Pharma & Biotech has concluded an agreement, under which GE Healthcare will deliver an off-the-shelf biologics facility to it in Guangzhou, China, by 2020. The company said that the new facility would give it “a strategic base in China to respond to growing demand for high-quality CDMO services in the country”.
DSM Sinochem Pharmaceuticals has new identity under private equity owner
Boehringer Ingelheim (BI) has started the construction of a new production facility for innovative drugs. The new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches.
The research-driven pharmaceutical company is investing €85 million (US$99.3 million) in Ingelheim, focusing on modern and flexible production.
Pharmaceutical giant Pfizer is reorganising its company into three businesses to help the company “achieve its growth potential”.
A science-based Innovative Medicines business will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables. These units possess significant therapeutic area expertise in the medical, commercial and patient experience domains and will provide a strong commercialisation platform for these medicines.
“Fail early and fail cheap” – this was the key message from Dr Magid Abou-Gharbia of the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy in Philadelphia, US.
